Opko Health, Inc.

As of June 30, 2026, OPKO Health, Inc. carries a market capitalization of 331.43B, placing it among publicly traded companies globally. Its enterprise value stands at 360.27B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

OPKO Health, Inc.'s next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, OPKO Health, Inc. has 745.95M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.95, and the price-to-book ratio stands at 0.94.

As of June 30, 2026, OPKO Health, Inc. trades at an EV/EBITDA multiple of 29.31 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.07 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 360.27B versus a market cap of 331.43B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, OPKO Health, Inc. maintains a current ratio of 3.35, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 33.62, indicating elevated leverage, while an interest coverage ratio of 0.92 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, OPKO Health, Inc. posted a negative return on equity (ROE) of -5.88, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.83, reflecting losses generated across the asset base. The company generates approximately 70.96M in revenue per employee across its workforce of 2,455.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.43 indicates how many times OPKO Health, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, OPKO Health, Inc. recorded an income tax benefit of -2.06B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -23.66B and -21.60B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, OPKO Health, Inc.'s stock has gained approximately 2.60% over the past 52 weeks. The 50-day moving average sits at 462.78, while the 200-day moving average is 405.31.

Over the twelve months ended June 30, 2026, OPKO Health, Inc. generated 174.25B in revenue and converted that into -21.60B in net income, yielding earnings per share of -28.24. EBITDA reached 12.29B, while operating income came in at -49.76B.

As of June 30, 2026, OPKO Health, Inc. holds 89.14B in cash and equivalents against 117.99B in total debt, resulting in a net debt position of 14.31B. Total book value stands at 350.98B, with working capital of 104.00B providing operational flexibility.

OPKO Health, Inc. produced -36.57B in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, OPKO Health, Inc. posted a gross margin of 40.77, reflecting its pricing power and cost economics. The operating margin of -28.56 and net profit margin of -12.40 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -10.76: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 4.72, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to OPKO Health, Inc. shareholders.

As of June 30, 2026, OPKO Health, Inc. has an Altman Z-Score of -3.17, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.